Barkan Omri A, Allweis Tanir M, Egozi Dana
From Department of Plastic and Reconstructive Surgery, Kaplan Medical Center, Rehovot, Israel.
Department of General Surgery, Kaplan Medical Center, Rehovot, Israel.
Plast Reconstr Surg Glob Open. 2025 Jul 18;13(7):e6960. doi: 10.1097/GOX.0000000000006960. eCollection 2025 Jul.
This study compared oncoplastic breast reconstruction (OBR) outcomes in patients with small breasts (cup sizes A-C, SB-OR) undergoing large tumor resections versus those with large breasts (cup size D+, LB-OR). It evaluated safety, complications, and aesthetic results in these challenging cases.
A retrospective review included 28 OBR patients (9 SB-OR, 19 LB-OR) treated between 2014 and 2018 at Kaplan Medical Center. Data collected included demographics, tumor characteristics, reoperation rates, complications, recurrence, and satisfaction (via BREAST-Q). Aesthetic outcomes were assessed by 12 medical professionals using a validated scale (0-10).
Relumpectomy rates for positive margins were 22.2% (SB-OR) versus 10.5% (LB-OR) ( = 0.4). SB-OR had no complications, whereas LB-OR had a 42.1% complication rate ( = 0.02). Patient satisfaction scores were similar (SB-OR: 74.4 ± 11.6; LB-OR: 73.1 ± 14.3; = 0.68). Cosmetic outcomes were comparable (SB-OR: 8.09 ± 0.88; LB-OR: 8.6 ± 1.17; = 0.33). One LB-OR patient had ipsilateral recurrence at 26 months (5.3% versus 0% in SB-OR; = 0.4), with a mean follow-up of 19.4 months in the SB-OR group (range: 1-45 mo).
OBR in patients with small breasts undergoing large resections demonstrated low complication rates (0%), oncological safety (no recurrences), and high patient satisfaction, comparable to the LB-OR group. Despite smaller sample sizes, SB-OR achieved similar aesthetic outcomes without the need for volume augmentation, suggesting it is a viable option for patients with small breasts.
本研究比较了接受大肿瘤切除术的小乳房患者(A - C罩杯,SB - OR)与大乳房患者(D + 罩杯,LB - OR)行肿瘤整形乳房重建(OBR)的效果。评估了这些具有挑战性病例中的安全性、并发症及美学效果。
一项回顾性研究纳入了2014年至2018年在卡普兰医疗中心接受治疗的28例行OBR的患者(9例SB - OR,19例LB - OR)。收集的数据包括人口统计学信息、肿瘤特征、再次手术率、并发症、复发情况及满意度(通过BREAST - Q量表)。12名医学专业人员使用经过验证的量表(0 - 10分)评估美学效果。
切缘阳性的再次切除率在SB - OR组为22.2%,在LB - OR组为10.5%(P = 0.4)。SB - OR组无并发症,而LB - OR组的并发症发生率为42.1%(P = 0.02)。患者满意度评分相似(SB - OR:74.4 ± 11.6;LB - OR:73.1 ± 14.3;P = 0.68)。美学效果相当(SB - OR:8.09 ± 0.88;LB - OR:8.6 ± 1.17;P = 0.33)。1例LB - OR患者在26个月时出现同侧复发(SB - OR组为5.3%,LB - OR组为0%;P = 0.4),SB - OR组的平均随访时间为19.4个月(范围:1 - 45个月)。
接受大切除手术的小乳房患者行OBR的并发症发生率低(0%),具有肿瘤学安全性(无复发),且患者满意度高,与LB - OR组相当。尽管样本量较小,SB - OR在无需增加容量的情况下取得了相似的美学效果,表明它是小乳房患者的一个可行选择。